Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MC4R | P32245 | 3/20 | 0.61 |
| ▸ | MC5R | P33032 | 2/20 | 0.61 |
| ▸ | MC3R | P41968 | 2/20 | 0.61 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.59 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.58 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.50 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.50 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.49 |
| ▸ | HTR2A | P28223 | 1/20 | 0.48 |
| ▸ | HTR2C | P28335 | 1/20 | 0.48 |
| ▸ | HTR2B | P41595 | 1/20 | 0.48 |
| ▸ | MAOA | P21397 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL7360106 | 0.98 | MC4R (0.59) | MC4RMC5RMC3RSIGMAR1CYP1A2 | |
| SCHEMBL130904 | 0.94 | MC4R (0.59) | MC4RMC5RMC3RSIGMAR1CYP1A2 | |
| SCHEMBL14979612 | 0.93 | MC4R (0.54) | MC4RMC5RMC3RSIGMAR1CYP1A2 | |
| SCHEMBL610921 | 0.93 | MC4R (0.54) | MC4RMC5RMC3RSIGMAR1CYP1A2 | |
| SCHEMBL136034 | 0.92 | MC4R (0.57) | MC4RMC5RMC3RSIGMAR1CYP1A2 | |
| Hydrochloric Acid SCHEMBL17260634 | 0.92 | MC4R (0.57) | MC4RMC5RMC3RSIGMAR1CYP1A2 | |
| SCHEMBL130385 | 0.92 | MC4R (0.57) | MC4RMC5RMC3RSIGMAR1CYP1A2 | |
| Hydrochloric Acid SCHEMBL8424014 | 0.90 | MC4R (0.56) | MC4RMC5RMC3RSIGMAR1CYP1A2 | |
| SCHEMBL38430 | 0.87 | MC4R (0.58) | MC4RMC5RMC3RSIGMAR1CYP1A2 | |
| SCHEMBL29860016 | 0.87 | MC4R (0.58) | MC4RMC5RMC3RSIGMAR1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112494644-B | Composite adjuvant, vaccine containing composite adjuvant and application | 中国医学科学院医学生物学研究所 | 2024-02-06 | — | — | CN | disclosed |
| CN-112494644-A | Compound adjuvant, vaccine containing compound adjuvant and application | 中国医学科学院医学生物学研究所 | 2021-03-16 | — | — | CN | disclosed |
| US-9745319-B2 | Irreversible covalent inhibitors of the GTPase K-Ras G12C | ARAXES PHARMA LLC (US) | 2017-08-29 | — | — | US | disclosed |
| US-20160257677-A1 | LARGE SUBSTITUTENT, NON-PHENOLIC OPIOIDS AND METHODS OF USE THEREOF | RENSSELAER POLYTECHNIC INSTITUTE (US) | 2016-09-08 | — | — | US | disclosed |
| US-20160031898-A1 | IRREVERSIBLE COVALENT INHIBITORS OF THE GTPASE K-RAS G12C | ARAXES PHARMA LLC | 2016-02-04 | — | — | US | disclosed |
| US-9156821-B2 | Large substituent, non-phenolic opioids and methods of use thereof | RENSSELAER POLYTECHNIC INSTITUTE (US) | 2015-10-13 | — | — | US | disclosed |
| US-20150051194-A1 | LARGE SUBSTITUENT, NON-PHENOLIC OPIOIDS AND METHODS OF USE THEREOF | RENSSELAER POLYTECHNIC INSTITUTE (US) | 2015-02-19 | — | — | US | disclosed |
| US-8901148-B2 | Large substituent, non-phenolic opioids and methods of use thereof | RENSSELAER POLYTECHNIC INSTITUTE (US) | 2014-12-02 | — | — | US | disclosed |
| EP-1512397-B1 | O-SUBSTITUTED HYDROXYARYL DERIVATIVES | INST MED MOLECULAR DESIGN INC (JP) | 2014-10-08 | — | — | EP | disclosed |
| EP-1924559-B1 | 8-CARBOXAMIDO-SUBSTITUTED-2 , 6-METHANO-3-BENZAZOCINES AND 3 - CARBOXAMIDO- SUBSTITUTED MORPHANES AS OPIOID RECEPTOR BINDING AGENTS | RENSSELAER POLYTECH INST (US) | 2014-04-16 | — | — | EP | disclosed |
| EP-1512397-A1 | O-SUBSTITUTED HYDROXYARYL DERIVATIVES | Institute of Medicinal Molecular Design, Inc. (JP) | 2005-03-09 | — | — | EP | disclosed |
| EP-1512396-A1 | INHIBITORS AGAINST THE ACTIVATION OF AP-1 AND NFAT | Institute of Medicinal Molecular Design, Inc. (JP) | 2005-03-09 | — | — | EP | disclosed |
| EP-1510207-A1 | THERAPEUTIC DRUG FOR DIABETES | Institute of Medicinal Molecular Design, Inc. (JP) | 2005-03-02 | — | — | EP | disclosed |
| EP-1510210-A1 | IMMUNITY-RELATED PROTEIN KINASE INHIBITORS | Institute of Medicinal Molecular Design, Inc. (JP) | 2005-03-02 | — | — | EP | disclosed |
| US-20040259877-A1 | Inhibitors against the production and release of inflammatory cytokines | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2004-12-23 | — | — | US | disclosed |
| EP-1352650-A1 | INHIBITORS AGAINST THE PRODUCTION AND RELEASE OF INFLAMMATORY CYTOKINES | Institute of Medicinal Molecular Design, Inc. (JP) | 2003-10-15 | — | — | EP | disclosed |
| US-6307090-B1 | OXALYL ENDCAPPED; CONTAINING A BIVALENT RADICAL OF PHOSPHOTYROSINE OR A PHOSPHOTYROSINE MIMETIC | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2001-10-23 | — | — | US | disclosed |
| US-6057371-A | TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS, GASTROINTESTINAL DISORDERS, DRUG ABUSE, ANGINA, MIGRAINE, HYPERTENSION AND DEPRESSION | VIRGINIA COMMONWEALTH UNIVERSITY (US) | 2000-05-02 | — | — | US | disclosed |
| EP-0846127-A1 | ACYLATED OLIGOPEPTIDE DERIVATIVES HAVING CELL SIGNAL INHIBITING ACTIVITY | Novartis AG (CH) | 1998-06-10 | — | — | EP | disclosed |
| WO-1997008193-A1 | ACYLATED OLIGOPEPTIDE DERIVATIVES HAVING CELL SIGNAL INHIBITING ACTIVITY | NOVARTIS AG (CH) | 1997-03-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150051194-A1 | LARGE SUBSTITUENT, NON-PHENOLIC OPIOIDS AND METHODS OF USE THEREOF | OPRK1, OPRM1, OPRD1 | MC4R 277/4885MC5R 438/4885MC3R 350/4885 |
| US-20160257677-A1 | LARGE SUBSTITUTENT, NON-PHENOLIC OPIOIDS AND METHODS OF USE THEREOF | OPRM1, OPRK1, SIGMAR1 | MC4R 323/4885MC5R 400/4885MC3R 306/4885 |
| US-20160031898-A1 | IRREVERSIBLE COVALENT INHIBITORS OF THE GTPASE K-RAS G12C | KRAS, HRAS, NRAS | MC4R 4745/4885MC5R 4800/4885MC3R 4688/4885 |
| US-20040259877-A1 | Inhibitors against the production and release of inflammatory cytokines | NFKBIA, IL1B, IKBKB | MC4R 2803/4885MC5R 2281/4885MC3R 3356/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.